Priya Marreddy
Technik-/Wissenschafts-/F&E-Leiter bei CONTEXT THERAPEUTICS INC.
Profil
Priya Marreddy is currently the Vice President-Clinical Operations at Context Therapeutics, Inc. Previously, she worked as the Head-Clinical Operations at Cornerstone Pharmaceuticals, Inc. She completed her graduate degree at the University of Pennsylvania and her undergraduate degree at George Washington University.
Aktive Positionen von Priya Marreddy
Unternehmen | Position | Beginn |
---|---|---|
CONTEXT THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2022 |
Ehemalige bekannte Positionen von Priya Marreddy
Unternehmen | Position | Ende |
---|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Priya Marreddy
George Washington University | Undergraduate Degree |
University of Pennsylvania | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CONTEXT THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |